A unified mechanism for aminopeptidase N-based tumor cell motility and tumor-homing therapy

Journal of Biological Chemistry

Volumn 289, Issue 50, 2014, Pages 34520-34529

  Liu, Chang ^a   Yang, Yang ^a   Chen, Lang ^a   Lin, Yi Lun ^a   Li, Fang ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; CRYSTAL STRUCTURE; CYTOLOGY; ENZYME ACTIVITY; PEPTIDES;

AMINO PEPTIDASE; ANTICANCER DRUG; CELL MOTILITY; ENZYMATIC ACTIVITIES; EXTRACELLULAR ENVIRONMENTS; EXTRACELLULAR MATRIX PROTEIN; HOMING PEPTIDE; TUMOR CELL MOTILITY;

TUMORS;

MICROSOMAL AMINOPEPTIDASE; PEPTIDE; SCLEROPROTEIN; ANTINEOPLASTIC AGENT; NGR PEPTIDE; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; CELL MOTILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; TUMOR CELL; TUMOR HOMING THERAPY; ANIMAL; CELL ADHESION; CELL MOTION; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PIG; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD13; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CRYSTALLOGRAPHY, X-RAY; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEIN CONFORMATION; SWINE;

EID: 84918824732     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.566802     Document Type: Article

References (45)

1. Wickström, M., Larsson, R., Nygren, P., and Gullbo, J. (2011) Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 102, 501-508
2. Mina-Osorio, P. (2008) The moonlighting enzyme CD13: old and new functions to target. Trends Mol. Med. 14, 361-371
3. Bauvois, B. (2004) Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 23, 317-329
4. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722-727
5. Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. (2000) Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18, 1185-1190
6. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380
7. Petrovic, N., Schacke, W., Gahagan, J. R., O'Conor, C. A., Winnicka, B., Conway, R. E., Mina-Osorio, P., and Shapiro, L. H. (2007) CD13/APN regulates endothelial invasion and filopodia fonnation. Blood 110, 142-150
8. Carl-McGrath, S., Lendeckel, U., Ebert, M., and Röcken, C. (2006) Ectopeptidases in tumour biology: a review. Histol. Histopathol. 21, 1339-1353
9. Chen, L., Lin, Y. L., Peng, G., and Li, F. (2012) Structural basis for multifunctional roles of mammalian aminopeptidase N. Proc. Natl. Acad. Sci. U.S.A. 109, 17966-17971
10. Fujii, H., Nakajima, M., Saiki, I., Yoneda, J., Azuma, I., and Tsuruo, T. (1995) Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin. Exp. Metastasis 13, 337-344
11. Kehlen, A., Lendeckel, U., Dralle, H., Langner, J., and Hoang-Vu, C. (2003) Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res. 63, 8500-8506
12. Hashida, H., Takabayashi, A., Kanai, M., Adachi, M., Kondo, K., Kohno, N., Yamaoka, Y., and Miyake, M. (2002) Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 122, 376-386
13. Chang, Y. W., Chen, S. C., Cheng, E. C., Ko, Y. P., Lin, Y. C., Kao, Y. R., Tsay, Y. G., Yang, P. C., Wu, C. W., and Roffler, S. R. (2005) CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells. Int. J. Cancer 116, 243-252
14. Menrad, A., Speicher, D., Wacker, J., and Herlyn, M. (1993) Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res. 53, 1450-1455
15. Saiki, I., Fujii, H., Yoneda, J., Abe, F., Nakajima, M., Tsuruo, T., and Azuma, I. (1993) Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer 54, 137-143
16. Fukasawa, K., Fujii, H., Saitoh, Y., Koizumi, K., Aozuka, Y., Sekine, K., Yamada, M., Saiki, I., and Nishikawa, K. (2006) Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett. 243, 135-143
17. Mina-Osorio, P., Winnicka, B., O'Conor, C., Grant, C. L., Vogel, L. K., Rodriguez-Pinto, D., Holmes, K. V., Ortega, E., and Shapiro, L. H. (2008) CD13 is a novel mediator of monocytic/endothelial cell adhesion. J. Leukocyte Biol. 84, 448-459
18. Carlsson, L., Ronquist, G., Eliasson, R., Egberg, N., and Larsson, A. (2006) Flow cytometric technique for determination of prostasomal quantity, size and expression of CD10, CD13, CD26 and CD59 in human seminal plasma. Int. J. Androl. 29, 331-338
19. Irazusta, J., Valdivia, A., Fernández, D., Agirregoitia, E., Ochoa, C., and Casis, L. (2004) Enkephalin-degrading enzymes in normal and subfertile human semen. J. Androl. 25, 733-739
20. González Buitrago, J. M., Navajo, J. A., García Diez, L. C., and Herruzo, A. (1985) Seminal plasma leucine aminopeptidase in male fertility. Andrologia 17, 139-142
21. Tani, K., Ogushi, F., Huang, L., Kawano, T., Tada, H., Hariguchi, N., and Sone, S. (2000) CD13/aminopeptidase N, a novel chemoattractant for T lymphocytes in pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 161, 1636-1642
22. Shimizu, T., Tani, K., Hase, K., Ogawa, H., Huang, L., Shinomiya, F., and Sone, S. (2002) CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum. 46, 2330-2338
23. Mina-Osorio, P., Shapiro, L. H., and Ortega, E. (2006) CD13 in cell adhesion: aminopeptidase N (CD13) mediates homotypic aggregation of monocytic cells. J. Leukocyte Biol. 79, 719-730
24. Arnaout, M. A., Goodman, S. L., and Xiong, J. P. (2002) Coming to grips with integrin binding to ligands. Curr. Opin. Cell Biol. 14, 641-651
25. Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., and Arnaout, M. A. (2001) Crystal structure of the extracellular segment of integrin αVβ3. Science 294, 339-345
26. Xiong, J. P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., and Arnaout, M. A. (2002) Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151-155
27. Desgrosellier, J. S., and Cheresh, D. A. (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22
28. Guo, W., and Giancotti, F. G. (2004) Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5, 816-826
29. Svensen, N., Walton, J. G., and Bradley, M. (2012) Peptides for cell-selective drug delivery. Trends Pharmacol. Sci. 33, 186-192
30. Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., and Ruoslahti, E. (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031-1035
31. Gregorc, V., Santoro, A., Bennicelli, E., Punt, C. J., Citterio, G., Timmer-Bonte, J. N., Caligaris Cappio, F., Lambiase, A., Bordignon, C., and van Herpen, C. M. (2009) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br. J. Cancer 101, 219-224
32. Gregorc, V., Citterio, G., Vitali, G., Spreafico, A., Scifo, P., Borri, A., Donadoni, G., Rossoni, G., Corti, A., Caligaris-Cappio, F., Del Maschio, A., Esposito, A., De Cobelli, F., Dell'Acqua, F., Troysi, A., Bruzzi, P., Lambiase, A., and Bordignon, C. (2010) Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur. J. Cancer 46, 198-206
33. Gregorc, V., Zucali, P. A., Santoro, A., Ceresoli, G. L., Citterio, G., De Pas, T. M., Zilembo, N., De Vincenzo, F., Simonelli, M., Rossoni, G., Spreafico, A., Grazia Viganò, M., Fontana, F., De Braud, F. G., Bajetta, E., Caligaris-Cappio, F., Bruzzi, P., Lambiase, A., and Bordignon, C. (2010) Phase II study of asparagine-glycine-arginine-human tumor necrosis factor α, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J. Clin. Oncol. 28, 2604-2611
34. Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., Schiff, D., Shapiro, W. R., Burdette-Radoux, S., Dropcho, E. J., Wittemer, S. M., Nippgen, J., Picard, M., and Nabors, L. B. (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610-5617
35. Eskens, F. A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Böttcher, S., Wynendaele, W., Drevs, J., Verweij, J., and van Oosterom, A. T. (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. Eur. J. Cancer 39, 917-926
36. Otwinowski, Z., and Minor, W. (1997) Processing of x-ray diffraction data. Methods Enzymol. 276, 307-326
37. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921
38. Murshudov, G. N., Vagin, A. A., Lebedev, A., Wilson, K. S., and Dodson, E. J. (1999) Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr. D Biol. Crystallogr. 55, 247-255
39. Yang, Y., Liu, C., Lin, Y. L., and Li, F. (2013) Structural insights into central hypertension regulation by human aminopeptidase A. J. Biol. Chem. 288, 25638-25645
40. Shor, A. C., Keschman, E. A., Lee, F. Y., Muro-Cacho, C., Letson, G. D., Trent, J. C., Pledger, W. J., and Jove, R. (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 67, 2800-2808
41. Chen, Y., Lu, B., Yang, Q., Fearns, C., Yates, J. R., 3rd, and Lee, J. D. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA-based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res. 69, 3713-3720
42. Peng, G., Sun, D., Rajashankar, K. R., Qian, Z., Holmes, K. V., and Li, F. (2011) Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. Proc. Natl. Acad. Sci. U.S.A. 108, 10696-10701
43. Du, L., Zhao, G., Yang, Y., Qiu, H., Wang, L., Kou, Z., Tao, X., Yu, H., Sun, S., Tseng, C. T., Jiang, S., Li, F., and Zhou, Y. (2014) A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus Spike protein. J. Virol. 88, 7045-7053
44. Di Matteo, P., Curnis, F., Longhi, R., Colombo, G., Sacchi, A., Crippa, L., Protti, M. P., Ponzoni, M., Toma, S., and Corti, A. (2006) Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.Mol. Immunol. 43, 1509-1518
45. Williams, M. J., Phan, I., Harvey, T. S., Rostagno, A., Gold, L. I., and Campbell, I. D. (1994) Solution structure of a pair of fibronectin type 1 modules with fibrin binding activity. J. Mol. Biol. 235, 1302-1311